TOP > 外国特許検索 > ANTIBODY FRAGMENT DEGRADING AND REMOVING ABNORMAL TDP-43

ANTIBODY FRAGMENT DEGRADING AND REMOVING ABNORMAL TDP-43 NEW

外国特許コード F190009978
整理番号 (S2018-0474-N0)
掲載日 2019年10月28日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2019JP010771
国際公開番号 WO 2019177138
国際出願日 平成31年3月15日(2019.3.15)
国際公開日 令和元年9月19日(2019.9.19)
優先権データ
  • 特願2018-049752 (2018.3.16) JP
発明の名称 (英語) ANTIBODY FRAGMENT DEGRADING AND REMOVING ABNORMAL TDP-43 NEW
発明の概要(英語) Disclosed is a modified antibody fragment consisting of an antibody fragment capable of binding to misfolded TDP-43 and a chaperone-mediated autophagy transit signal peptide, wherein: the antibody fragment includes a heavy-chain variable region that comprises heavy chain CDR1 comprising the amino acid sequence GFNIKDYY (SEQ ID NO: 1), heavy chain CDR2 comprising the amino acid sequence IDPEDGET (SEQ ID NO: 2) and heavy chain CDR3 comprising the amino acid sequence TIIYYYGSRYVDY (SEQ ID NO: 3), each sequence optionally having not more than 3 amino acid substitutions, and/or a light-chain variable region that comprises light chain CDR1 comprising the amino acid sequence SSISSSY(SEQ ID NO: 4), light chain CDR2 comprising the amino acid sequence RTS and light chain CDR3 comprising the amino acid sequence QQGSSIPLT (SEQ ID NO: 5), each sequence optionally having not more than 3 amino acid substitutions; and the antibody fragment is scFv, VH or VL.
従来技術、競合技術の概要(英語) BACKGROUND ART
Is the most refractory nerve injuries Amyotrophic Lateral Sclerosis (ALS) amyotrophic lateral sclerosis and dementia has a prevalence of 2 in the second fronto-temporal dementia (FTD) is a nuclear protein protein TDP-43 (TAR DNA-binding protein of 43kDa) causes have been identified. FTD is in ALS and TDP-43 escape from the nucleus, the cytoplasm is the mechanism to form an aggregation condition is unknown.
TDP-43 is, in the ALS FTD and ubiquitination is observed a very high in the enclosure is known. Current, exhibits an abnormal pathology findings TDP-43 is a disease, a disease group and referred to as TDP-43 positioned puroteinopachi, the functions of the various reports from the abnormal condition of the TDP-43 ALS be increasingly essential.
In this way the physiological and pathological TDP-43 to elucidate the function of the ALS could lead to overcome, such as the world has been studied energetically. Of the TDP-43 puroteinopachi pathological findings are important and most clearly, and a decrease in the nuclear staining of the TDP-43 body formation in the cytoplasm. To elucidate the function of the localization of the ectopic the ALS disease is essential for the understanding of the present invention.
TDP-43 may have a molecular structure, RNA-binding region (RRM) 2 and one end of the region C and glycine-rich, nuclear localization signal (NLS), and nuclear export signal (NES) has. TDP-43 into somatic cells of all constant and expressed, mainly localized to the nucleus. In the ALS and FTD in normal tissues from the nuclear localization without exception, ectopic TDP-43 influence on the localization conditions have been noted. TDP-43 positive cell enclosure, a high frequency which have been fragmented and contains a TDP-43.
Also, in addition to the ALS and FTD TDP-43 as ectopic exhibits localized disease, syndrome Perry, low-grade glioma, Alzheimer's disease, Huntington's disease, Pick's disease, Parkinson's disease, Lewy body disease, corticobasal degeneration, inclusion body myositis, B-cell lymphoma (M phase) and the like have been reported.
The inventors of the present invention, (1) which is independent of the TDP-43 disease pathogenesis of toxic normal structure is how to structure the transformation structure, and (2) how abnormal structures from the viewpoint that the capture has been studied. As a result, the cysteine residues of the TDP-43 RRM1 is important to maintain a normal structure, the modification of the abnormality found in the brain of the ALS and FTD abnormal aggregates can reproduce in vitro (Patent Document 1) are demonstrated. In addition, such abnormal aggregation and abnormally to the localized exposed to the outside in the TDP-43 molecules to identify the sequence, the sequence in the target, accumulate the aggregate of the TDP-43 risk of the onset of the disease can be predicted and reported (Patent Document 2).
In addition, in Patent Document 3 and 4, the detection antibody TDP-43 is reported, the antibody recognizes the aggregate of these, an advanced stage in a state in which a structural change of the earlier as a therapeutic target is obtained.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • SHIGA UNIVERSITY OF MEDICAL SCIENCE
  • 発明者(英語)
  • URUSHITANI, Makoto
  • TAMAKI, Yoshitaka
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JO JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG

PAGE TOP

close
close
close
close
close
close